Psilocybin and psychedelic-assisted therapy (PAT) have gained renewed interest due to recent findings that PAT can enhance therapeutic outcomes. In 2019, the U.S. Food & Drug Administration (FDA) approved breakthrough therapy status to psilocybin for the treatment of depression, but PAT has yet to be approved as a therapeutic treatment for mental health disorders. Should the FDA approve PAT, medical students will serve as gatekeepers to PAT.
Methods:
Medical students (n = 295) were surveyed and randomized to two terminology conditions (i.e., “psilocybin” or “magic mushrooms, MMs”) assessing their attitudes, knowledge, and beliefs.
Results:
Regardless of the terminology utilized, medical students held overall positive attitudes but their attitudes were significantly more positive when the term “psilocybin” was used. Furthermore, experience with psychedelics was associated with significantly more positive attitudes, beliefs, and higher self-rated knowledge. Finally, attitudes and beliefs were significant predictors of medical students' willingness to recommend PAT, if FDA approved, after controlling for covariates (e.g., personal experience with psychedelics).
Conclusions:
Despite some limitations, based on this study, using the term “psilocybin” might be preferable over “MMs” in a research or educational context. Although personal experience positively affects opinions toward psychedelics, beliefs and attitudes seem to be more relevant when it comes to actual medical advice.
Get full access to this article
View all access options for this article.
References
1.
OsmondH. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci, 1957; 66(3):418–434; doi: 10.1111/j.1749-6632.1957.tb40738.x
2.
Carhart-HarrisRL, BolstridgeM, DayCMJ, et al.Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl), 2018; 235(2):399–408; doi: 10.1007/s00213-017-4771-x
3.
DavisAK, Agin-LiebesG, EspañaM, et al.Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J Psychoactive Drugs, 2022; 54(4):309–318; doi: 10.1080/02791072.2021.1971343
4.
LearyT, LitwinGH, MetznerR. Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis, 1963; 137(6):561–573; doi: 10.1097/00005053-196312000-00007
5.
RosemanL, NuttDJ, Carhart-HarrisRL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol, 2018; 8:974; doi: 10.3389/fphar.2017.00974
6.
GoldbergSB, PaceBT, NicholasCR, et al.The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res, 2020; 284:112749; doi: 10.1016/j.psychres.2020.112749
7.
LiN-X, HuY-R, ChenW-N, et al.Dose effect of psilocybin on primary and secondary depression: A preliminary systematic review and meta-analysis. J Affect Disord, 2022; 296:26–34; doi: 10.1016/j.jad.2021.09.041
8.
VargasAS, Luís Â, BarrosoM, et al.Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases—A systematic review and meta-analysis of clinical trials. Biomedicines, 2020; 8(9):331; doi: 10.3390/biomedicines8090331
9.
LuomaJB, ChwylC, BathjeGJ, et al.A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs, 2020; 52(4):289–299; doi: 10.1080/02791072.2020.1769878
10.
WheelerSW, DyerNL. A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychol Conscious Theory Res Pract, 2020; 7(3):279–315; doi: 10.1037/cns0000237
11.
RahhalN.A Step Closer to Legalizing Magic Mushrooms as FDA Lets Second Research Group Us the ‘Breakthrough’ Drug in Clinical Trial to Treat Patients with Depression. Daily Mail: United Kingdom; 2019.
12.
BogenschutzMP, RossS, BhattS, et al.Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 2022; 79(10):953; doi: 10.1001/jamapsychiatry.2022.2096
13.
Carhart-HarrisRL, LeechR, WilliamsTM, et al.Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry, 2012; 200(3):238–244; doi: 10.1192/bjp.bp.111.103309
14.
DavisAK, BarrettFS, MayDG, et al.Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 2021; 78(5):481; doi: 10.1001/jamapsychiatry.2020.3285
15.
Garcia-RomeuA, GriffithsR, JohnsonM. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev, 2015; 7(3):157–164; doi: 10.2174/1874473708666150107121331
16.
RossS, BossisA, GussJ, et al.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol (Oxf), 2016; 30(12):1165–1180; doi: 10.1177/0269881116675512
17.
YadenDB, PotashJB, GriffithsRR. Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry, 2022; 79(10):943; doi: 10.1001/jamapsychiatry.2022.2546
18.
GardnerJ, CarterA, O'BrienK, et al.Psychedelic-assisted therapies: The past, and the need to move forward responsibly. Int J Drug Policy, 2019; 70:94–98; doi: 10.1016/j.drugpo.2019.05.019
19.
CornfieldZAD, HubleyAM. Counselors' attitudes towards working with clients with substance use disorders. Couns Psychol, 2020; 48(5):630–656; doi: 10.1177/0011000020915451
20.
ReaganMD. Physicians as gatekeepers. N Engl J Med, 1987; 317(27):1731–1734; doi: 10.1056/NEJM198712313172709
21.
RønneST, RosenbækF, PedersenLB, et al.Physicians' experiences, attitudes, and beliefs towards medical cannabis: A systematic literature review. BMC Fam Pract, 2021; 22(1):212; doi: 10.1186/s12875-021-01559-w
22.
BarnettBS, SiuWO, PopeHG. A survey of American psychiatrists' attitudes toward classic hallucinogens. J Nerv Ment Dis, 2018; 206(6):476–480; doi: 10.1097/NMD.0000000000000828
23.
CorriganK, HaranM, McCandlissC, et al.Psychedelic perceptions: Mental health service user attitudes to psilocybin therapy. Ir J Med Sci, 1971–2022;191(3):1385–1397; doi: 10.1007/s11845-021-02668-2
24.
MeyerTD, MeirP, LexC, et al.Magic mushrooms—An exploratory look at how mental health professionals feel and think about Psilocybin. Psychiatry Res, 2022; 316:114727; doi: 10.1016/j.psychres.2022.114727
25.
AdayJS, SkilesZ, EatonN, et al.Personal psychedelic use is common among a sample of psychedelic therapists: Implications for research and practice. Psychedelic Med, 2023; 1(1):27–37; doi: 10.1089/psymed.2022.0004
26.
BeaussantY, SandersJ, SagerZ, et al.Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert clinicians' and investigators' perspectives. J Palliat Med, 2020; 23(10):1323–1334; doi: 10.1089/jpm.2019.0603
27.
HordowiczM, KlimkiewiczA, JaroszJ, et al.Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: A systematic literature review. Drug Alcohol Depend, 2021; 221:108652; doi: 10.1016/j.drugalcdep.2021.108652
28.
JamesBO, OmoaregbaJO. Nigerian medical students' opinions about individuals who use and abuse psychoactive substances. Subst Abuse, 2013; 7:109–116; doi: 10.4137/SART.S12129
29.
NielsonEM, GussJ. The influence of therapists' first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. J Psychedelic Stud, 2018; 2(2):64–73; doi: 10.1556/2054.2018.009
30.
AjzenI.Attitudes, Personality and Behavior, 2nd ed. McGraw-Hill International (UK) Ltd.: Maidenhead, United Kingdom; 2005.
31.
AjzenI, JoyceN, SheikhS, et al.Knowledge and the prediction of behavior: The role of information accuracy in the theory of planned behavior. Basic Appl Soc Psychol, 2011; 33(2):101–117; doi: 10.1080/01973533.2011.568834
32.
FeingoldD. Attitudes towards substance use disorders among students in the social sciences: The role of gender and terminology. Subst Use Misuse, 2020; 55(3):519–523; doi: 10.1080/10826084.2019.1683199
33.
MillerAN, BharathanA, DuvuuriVNS, et al.Use of seven types of medical jargon by male and female primary care providers at a university health center. Patient Educ Couns, 2022; 105(5):1261–1267; doi: 10.1016/j.pec.2021.08.018
34.
AllenKA, CharpentierV, HendricksonMA, et al.Jargon be gone—Patient preference in doctor communication. J Patient Exp, 2023; 10:237437352311589; doi: 10.1177/23743735231158942
35.
OsgoodCE, SuciGJ, TannenbaumPH. The Measurement of Meaning. University of Illinois Press: Urbana-Champaign, IL, USA; 1978.
36.
SiegelJT, DonaldsonCD, CranoWD. Application of vested interest theory to prevention of non-medical prescription stimulant and marijuana use: Unforeseen benefits of attitude-behavior inconsistency. Drug Alcohol Depend, 2019; 194:210–215; doi: 10.1016/j.drugalcdep.2018.10.007
37.
BalneavesLG, AlrajaA, ZiemianskiD, et al.A national needs assessment of Canadian nurse practitioners regarding cannabis for therapeutic purposes. Cannabis Cannabinoid Res, 2018; 3(1):66–73; doi: 10.1089/can.2018.0002
38.
CrowleyD, CollinsC, DelargyI, et al.Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: Results from a national survey. Harm Reduct J, 2017; 14(1):4; doi: 10.1186/s12954-016-0129-7
39.
MeirP, TaylorL, SoaresJC, et al.Psychotherapists' openness to engage their patients in psilocybin-assisted therapy for mental health treatment. J Affect Disord, 2023; 323:748–754; doi: 10.1016/j.jad.2022.12.050
40.
HilliardRC, WatsonJC, ZizziSJ. Stigma, attitudes, and intentions to seek mental health services in college student-athletes. J Am Coll Health, 2022; 70(5):1476–1485; doi: 10.1080/07448481.2020.1806851
41.
LiC-H, ChaoP-J. Impact of emotional contagion through social network sites on travel willingness in the pandemic. J Qual Assur Hosp Tour, 2022; 1–18; doi: 10.1080/1528008X.2022.2160858
42.
IBM Corp. IBM SPSS Statistics for Windows. 2021.
43.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
44.
SznitmanSR, Van RijswijkL, CousijnJ. Cannabis use as a predictor and outcome of positive and negative affect in college students: An ecological momentary assessment study. Addict Behav, 2022; 128:107221; doi: 10.1016/j.addbeh.2021.107221
45.
ShalitN, RehmJ, Lev-RanS. Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III. Addict Behav, 2019; 89:35–43; doi: 10.1016/j.addbeh.2018.09.020
46.
YouGov. Psychedelic Drugs: YouGov Poll: July 22–25, 2022. YouGov, 2022.
47.
PapazisisG, SiafisS, TsakiridisI, et al.Prevalence of cannabis use among medical students: A systematic review and meta-analysis. Subst Abuse, 2018; 12:117822181880597; doi: 10.1177/1178221818805977
48.
SmithG. Does gender influence online survey participation?: A record-linkage analysis of university faculty online survey response behavior. ERIC Doc Reprod Serv No, 2008;(501717):1–21.
49.
KargboRB. Psilocybin therapeutic research: The present and future paradigm. ACS Med Chem Lett, 2020; 11(4):399–402; doi: 10.1021/acsmedchemlett.0c00048
50.
BreeksemaJJ, NiemeijerAR, KredietE, et al.Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs, 2020; 34(9):925–946; doi: 10.1007/s40263-020-00748-y
